Developer docs
API playgroundTry for free, no card

Search company profiles

Metacrine

Full company profile

uuid00055x2

Namestring
Metacrine
Websiteurl
metacrine.com
Company typeenum
Private
Founded yearint
2015
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceutical, drug development pipeline, small molecule therapeutics, metabolic disease drugs, liver disease therapeutics
Industry2 codes
1Gastroenterology & Hepatology Pharmaceuticals
CodeHLAIAAAIPrimaryYes
2Translational Medicine & Biomarkers
CodeHLAIALAFPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
Social media profiles1 record
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Metacrine is a clinical-stage biopharmaceutical company developing an innovative pipeline of best-in-class drug candidates. The company focuses on discovering and advancing small-molecule therapeutics, with emphasis on liver and metabolic disease indications. As a pre-commercial stage company, its offering centers on proprietary drug candidates progressing through clinical development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Clinical-stage drug candidate pipeline
CategoryClinical-stage Biopharmaceuticals
Description

A pipeline of proprietary small-molecule drug candidates in clinical development, targeting liver and metabolic diseases, intended for future out-licensing, partnership, or commercialization with larger pharmaceutical companies.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Genfit
TypeDirect peer
Description

Late-stage NASH pipeline (elafibranor, icosabutate) with similar clinical-stage profile and FXR/PPAR mechanistic focus.

289bio
TypeDirect peer
Description

Clinical-stage developer of pegozafermin for NASH/MASH; similar company size, stage, and hepatology therapeutic focus.

3Equillium
TypeOthers
Description

Clinical-stage immunology biotech that entered into a merger transaction with Metacrine in 2022; directly relevant as the corporate successor / combining entity.

4Viking Therapeutics
TypeDirect peer
Description

Clinical-stage biotech with metabolic liver-disease programs (VK2809, VK2735) and a comparable small-cap profile to Metacrine.

5Terns Pharmaceuticals
TypeEmerging player
Description

Clinical-stage developer with NASH programs (TERN-101, FXR agonist) — directly comparable mechanism and indication to Metacrine's FXR pipeline.

6Akero Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH/NASH; comparable small-cap metabolic liver-disease developer.

7Gilead Sciences
TypeBroad incumbent
Description

Major pharma with broad NASH/liver-disease programs (cilofexor, selonsertib) including FXR-targeted assets; competes with Metacrine as a potential acquirer or partner.

8Novo Nordisk
TypeBroad incumbent
Description

Global pharma with significant metabolic-disease and emerging MASH/NASH presence; potential strategic acquirer for Metacrine's FXR assets.

9Intercept Pharmaceuticals
TypeDirect peer
Description

Pioneer in FXR agonist development for NASH/PBC with obeticholic acid; the most directly comparable clinical-stage-to-commercial liver-disease peer to Metacrine's FXR-focused pipeline.

10Madrigal Pharmaceuticals
TypeDirect peer
Description

Developer of resmetirom (Rezdiffra), an approved therapy for NASH/MASH; directly competes with Metacrine in the same liver-disease therapeutic area.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Metacrine

Clinical-stage Biopharmaceuticalsmetacrine.com

Metacrine firmographics

Firmographics
Name
Metacrine
Website
https://metacrine.com
Company type
Private
Founded year
2015
Headcount range
11–50 employees
Ownership category
akta.pro rank

Metacrine industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
akta.pro secondary industry
Translational Medicine & Biomarkers (HLAIALAF)

Keywords

  • Clinical-stage biopharmaceutical
  • Drug development pipeline
  • Small molecule therapeutics
  • Metabolic disease drugs
  • Liver disease therapeutics

Where Metacrine is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Metacrine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Metacrine product offering

Product offering

Core offering

Metacrine is a clinical-stage biopharmaceutical company developing an innovative pipeline of best-in-class drug candidates. The company focuses on discovering and advancing small-molecule therapeutics, with emphasis on liver and metabolic disease indications. As a pre-commercial stage company, its offering centers on proprietary drug candidates progressing through clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical-stage drug candidate pipeline A pipeline of proprietary small-molecule drug candidates in clinical development, targeting liver and metabolic diseases, intended for future out-licensing, partnership, or commercialization with larger pharmaceutical companies.

Companies that use Metacrine

Customer profile

Ideal customer profiles1 record

Metacrine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Metacrine partnerships and signals

Strategic signal

Recent moves4 records

Metacrine competitors and assessment

Company assessment

Direct peers

  • Genfit: Late-stage NASH pipeline (elafibranor, icosabutate) with similar clinical-stage profile and FXR/PPAR mechanistic focus.
  • 89bio: Clinical-stage developer of pegozafermin for NASH/MASH; similar company size, stage, and hepatology therapeutic focus.
  • Viking Therapeutics: Clinical-stage biotech with metabolic liver-disease programs (VK2809, VK2735) and a comparable small-cap profile to Metacrine.
  • Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH/NASH; comparable small-cap metabolic liver-disease developer.
  • Intercept Pharmaceuticals: Pioneer in FXR agonist development for NASH/PBC with obeticholic acid; the most directly comparable clinical-stage-to-commercial liver-disease peer to Metacrine's FXR-focused pipeline.
  • Madrigal Pharmaceuticals: Developer of resmetirom (Rezdiffra), an approved therapy for NASH/MASH; directly competes with Metacrine in the same liver-disease therapeutic area.

Others

  • Equillium: Clinical-stage immunology biotech that entered into a merger transaction with Metacrine in 2022; directly relevant as the corporate successor / combining entity.

Emerging players

  • Terns Pharmaceuticals: Clinical-stage developer with NASH programs (TERN-101, FXR agonist) — directly comparable mechanism and indication to Metacrine's FXR pipeline.

Broad incumbents

  • Gilead Sciences: Major pharma with broad NASH/liver-disease programs (cilofexor, selonsertib) including FXR-targeted assets; competes with Metacrine as a potential acquirer or partner.
  • Novo Nordisk: Global pharma with significant metabolic-disease and emerging MASH/NASH presence; potential strategic acquirer for Metacrine's FXR assets.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Metacrine social profiles

Digital presence

Metacrine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Metacrine leadership team

Management profile

Number of profiles

Profiles5 records

Metacrine funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Metacrine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metacrine

What does Metacrine do?

Metacrine is a clinical-stage biopharmaceutical company developing an innovative pipeline of best-in-class drug candidates. The company focuses on discovering and advancing small-molecule therapeutics, with emphasis on liver and metabolic disease indications. As a pre-commercial stage company, its offering centers on proprietary drug candidates progressing through clinical development.

When was Metacrine founded?

Metacrine was founded in 2015. It employs 11 to 50 people.

Where is Metacrine based?

Metacrine is headquartered in San Diego, United States, in the North America region.

Who are Metacrine's main competitors?

Direct peers on record are Genfit, 89bio, Viking Therapeutics, Akero Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Equillium is listed as an others. Terns Pharmaceuticals is listed as an emerging player. Broad incumbents are Gilead Sciences and Novo Nordisk.

Does Metacrine have an API?

No public API is recorded for Metacrine.

What industry is Metacrine in?

Metacrine's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds MTCR, OFIX, APEN, and TCFC Shareholders About Its Ongoing InvestigationsWeiss Law, a New York-based law firm, announced ongoing investigations into possible breaches of fiduciary duty by the boards of directors of four companies — Metacrine, Inc., Orthofix Medical Inc., Apollo Endosurgery, Inc., and The Community Financial Corporation — in connection with their respective proposed acquisitions or mergers. The investigations cover four separate transactions: Metacrine's acquisition by Equillium (valued at approximately $26 million with a 25% premium), Orthofix's acquisition by SeaSpine (implied per-share consideration of $3.04), Apollo Endosurgery's acquisition by Boston Scientific ($10.00 per share in cash), and Community Financial's merger with Shore Bancshares (implied per-share consideration of $40.71). The law firm is reaching out to shareholders of the target companies to discuss their rights and potential legal remedies.BenzingaMetacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday - Equillium (NASDAQ:EQ)Metacrine and Equillium mutually agreed to terminate their definitive merger agreement, causing Metacrine shares to rise 5.4% in after-hours trading while Equillium shares fell 6.3%. The article also highlights other market movements, including Oragenics' reverse stock split and Pintec Technology's significant revenue decline.PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing InvestigationsWeiss Law has announced ongoing investigations into possible breaches of fiduciary duty and other violations of law by the boards of directors of four companies in connection with separate M&A transactions. The investigations cover Equillium's proposed takeover of Metacrine (estimated at approximately $26 million in stock), Imago BioSciences' tender offer by a Merck subsidiary ($36.00 per share in cash), Metacrine's acquisition by Equillium, and Opiant Pharmaceuticals' proposed takeover by Indivior PLC ($20.00 per share plus contingent value rights up to $8.00).PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.Weiss Law has announced an investigation into possible breaches of fiduciary duty by the board of directors of Metacrine, Inc. in connection with its acquisition by Equillium, Inc., a deal valued at approximately $26 million with a 25% premium over net cash delivered at closing. The law firm is examining whether Metacrine's board acted in shareholders' best interests, whether the merger consideration adequately compensates shareholders, and whether all material information about the transaction was fully disclosed.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNBE, CYBE, EQ, MNRL, RMEDHalper Sadeh LLC, an investor rights law firm, announced investigations into five companies regarding potential violations of federal securities laws and breaches of fiduciary duties related to pending transactions. The companies under investigation are KnowBe4 (being acquired by Vista Equity Partners for $24.90 per share), CyberOptics (being acquired by Nordson Corporation for $54.00 per share), Equillium (merging with Metacrine Inc.), Brigham Minerals (merging with Sitio Royalties Corp.), and Ra Medical Systems (merging with Catheter Precision Inc.). The law firm indicated it may seek increased consideration for shareholders, additional disclosures, or other relief on behalf of shareholders.BenzingaMetacrine To Slash Its Workforce By 50%Metacrine Inc announced it will reduce its workforce by 50% as part of a restructuring to conserve cash for its drug development programs after abandoning its NASH program in October due to a toxicology study flagging potential delays. The biotech received FDA approval for a Phase 2 trial of its FXR agonist MET642 for ulcerative colitis, while holding approximately $76.4 million in cash sufficient to fund operations through 2023. The company's shares trade at $0.49, significantly below its 2020 IPO price of $13 per share.BenzingaMetacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients - Eli Lilly (NYSE:LLY)Metacrine Inc reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly's Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH) patients. The trial demonstrated that LDL-cholesterol increases were consistent with previous studies and liver fat content at 12 weeks showed reduction in monotherapy arms with additive effects in the combination regimen. All regimens had favorable safety profiles with no treatment-related serious adverse events reported across any cohorts.Benzinga35 Stocks Moving In Friday's Mid-Day Session - Agenus (NASDAQ:AGEN)A range of stocks experienced significant price movements during Friday's mid-day trading session, with gainers led by Phunware (up 1099%) and Digital World Acquisition (up 216.5%), while losers included Metacrine (down 56.3%) and Ocular Therapeutix (down 33.3%). Notable movers were driven by various catalysts including earnings results, clinical trial updates, IPO activity, and strategic announcements. The article aggregates price changes for approximately 35 stocks, capturing both companies with reported developments and those moving on market sympathy or unexplained momentum.BenzingaWhy Metacrine's Stock Is Trading Higher TodayMultiple firms initiated bullish analyst coverage on Metacrine (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on liver and gastrointestinal disease therapies, driving the stock higher on Monday. Shares traded up 6.83% to $10.86, with the stock having a 52-week range between $16.19 and $9.06. The analyst coverage initiation signals renewed institutional interest in the company's clinical development programs.PR NewswireMetacrine to Present at 30th Annual ROTH Conference and H.C. Wainwright & Co. 2nd Annual NASH Investor ConferenceMetacrine, Inc., a privately held biotechnology company headquartered in San Diego, announced that President and CEO Ken Song will participate in two upcoming investor conferences in March 2018. At the 30th Annual ROTH Conference in Dana Point, CA, Dr. Song will deliver a corporate presentation and participate in a NASH panel discussion on FXR agonists. He will also present at the H.C. Wainwright & Co. 2nd Annual NASH Investor Conference in New York.